Escherichia Enfeksiyonları
Özet
Escherichia coli (E.coli) çoğunlukla insanlarda ve hayvanlarda gastrointestinal (GI) ve idrar yolu enfeksiyonlarıyla ilişkilendirilir, ancak zatürre, sepsis ve menenjit gibi daha ciddi sistemik veya invaziv enfeksiyonlara da neden olabilir. Escherichia cinsi insan vücudunda bol miktarda bulunur, gastrointestinal sistemi kolonize eder, ancak doğru toksin ve yapışma faktörleri cephaneliğiyle donatıldığında gastroenteritten menenjite kadar enfeksiyonlara neden olabilir. Bu bölümde genel taksonomi, epidemiyoloji ve virülansın temel yönlerini, bu cinsler içindeki türlerin tanımlanması ve sınıflandırılması için kültüre bağlı ve kültürden bağımsız metodolojilerle birlikte ele alinacaktir. Ayrıca, E.coli antimikrobiyal direnç modellerindeki son eğilimler ve önerilen duyarlılık test yöntemleri ve yorumlayıcı kriterlerdeki güncellemeler tartisilacaktir.
Referanslar
Humphries, R. M., Faron, M. L., Dekker, J. P., Ledeboer, N. A., & Buchan, B. W. Escherichia and Shigella. 1-32. https://doi.org/10.1002/9781683670438.mcm0039, Manual of Clinical Microbiology Section II. Bacteriology Gram-Negative Bacteria Section Editor: Patricia Simner, Volume Editor: Robin Patel Editors in Chief: Karen C. Carroll and Michael A. PfallerISBN (Print): 9781555819835 ISBN (Online): 9781683670438
BK Markey, FC Leonard, M Archambault, A Cullinane, D Maguire AIMLS Clinical Veterinary Microbiology, Second edition , Section 2, Bacteriology, Esherichia coli, 250-251.First edition 1994 Second edition 2013, ISBN 9780723432371
Lawrence JG, Ochman H, Hartl DL. 1991. Molecular and evolutionary relationships among enteric bacteria. J Gen Microbiol 137:1911–1921
Lindsey RL, Fedorka-Cray PJ, Abley M, Turpin JB, Meinersmann RJ. 2015. Evaluating the occurrence of Escherichia albertii in chicken carcass rinses by PCR, VITEK analysis, and sequencing of the rpoB gene. Appl Environ Microbiol 81:1727–1734
Brenner DJ, Fanning GR, Skerman FJ, Falkow S. 1972. Polynucleotide sequence divergence among strains of Escherichia coli and closely related organisms. J Bacteriol 109:953–965. 8. Takahashi M, Kryukov K, Saitou N. 2009. Estimation of bacterial species phylogeny through oligonucleotide frequency distances. Genomics 93:525–533.
Chaudhuri RR, Henderson IR. 2012. The evolution of the Escherichia coli phylogeny. Infect Genet Evol 12:214–226.
Sims GE, Kim SH. 2011. Whole-genome phylogeny of Escherichia coli/Shigella group by feature frequency profiles (FFPs). Proc Natl Acad Sci USA 108:8329–8334.
Touchon M, Perrin A, de Sousa JAM, Vangchhia B, Burn S, O’Brien CL, Denamur E, Gordon D, Rocha EP. 2020. Phylogenetic background and habitat drive the genetic diversification of Escherichia coli. PLoS Genet 16:e1008866.
Smith JL, Fratamico PM, Gunther NW. 2007. Extraintestinal pathogenic Escherichia coli. Foodborne Pathog Dis 4:134–163.
Farmer JJ III, Davis BR, Hickman-Brenner FW, McWhorter A, Huntley-Carter GP, Asbury MA, Riddle C, Wathen-Grady HG, Elias C, Fanning GR. 1985. Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens. J Clin Microbiol 21:46–76.
Standridge J. 2008. E. coli as a public health indicator of drinking water quality. J Am Water Works Assoc 100:65–75.
Dewey-Mattia D, Manikonda K, Hall AJ, Wise ME, Crowe SJ. 2018. Surveillance for foodborne disease outbreaks—United States, 2009–2015. MMWR Surveill Summ 67:1–11.
Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. 2013. Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev 26:822–880.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. 2015. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13:269–284.
Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN. 2019. The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 63:e00355–19.
Hinenoya A, Li XP, Zeng X, Sahin O, Moxley RA, Logue CM, Gillespie B, Yamasaki S, Lin J. 2021. Isolation and characterization of Escherichia albertii in poultry at the preharvest level. Zoonoses Public Health 68:213–225.
Hinenoya A, Nagano K, Awasthi SP, Hatanaka N, Yamasaki S. 2020. Prevalence of Escherichia albertii in raccoons (Procyon lotor), Japan. Emerg Infect Dis 26:1304–1307.
Nicolle LE. 2014. Catheter associated urinary tract infections. Antimicrob Resist Infect Control 3:23.
Tandogdu Z, Cai T, Koves B, Wagenlehner F, Bjerklund Johansen TE. 2016. Urinary tract infections in immunocompromised patients with diabetes, chronic kidney disease, and kidney transplant. Eur Urol Focus 2:394–399.
Olesen B, Hansen DS, Nilsson F, Frimodt-Møller J, Leihof RF, Struve C, Scheutz F, Johnston B, Krogfelt KA, Johnson JR. 2013. Prevalence and characteristics of the epidemic multiresistant Escherichia coli ST131 clonal group among extended-spectrum beta-lactamase-producing E. coli isolates in Copenhagen, Denmark. J Clin Microbiol 51:1779–1785.
Leber AL, Everhart K, Balada-Llasat JM, Cullison J, Daly J, Holt S, Lephart P, Salimnia H, Schreckenberger PC, DesJarlais S, Reed SL, Chapin KC, LeBlanc L, Johnson JK, Soliven NL, Carroll KC, Miller JA, Dien Bard J, Mestas J, Bankowski M, Enomoto T, Hemmert AC, Bourzac KM. 2016. Multicenter evaluation of BioFire FilmArray Meningitis/ Encephalitis Panel for detection of bacteria, viruses, and yeast in cerebrospinal fluid specimens. J Clin Microbiol 54:2251–2261.
Gyles CL. 2007. Shiga toxin-producing Escherichia coli: an overview. J Anim Sci 85(Suppl_13):E45–E62.
Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. 2005. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982–2002. Emerg Infect Dis 11:603–609.
Qadri F, Svennerholm AM, Faruque AS, Sack RB. 2005. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev 18:465–483.
Ochoa TJ, Contreras CA. 2011. Enteropathogenic Escherichia coli infection in children. Curr Opin Infect Dis 24:478–483.
Hebbelstrup Jensen B, Olsen KE, Struve C, Krogfelt KA, Petersen AM. 2014. Epidemiology and clinical manifestations of enteroaggregative Escherichia coli. Clin Microbiol Rev 27:614–630.
Okhuysen PC, Dupont HL. 2010. Enteroaggregative Escherichia coli (EAEC): a cause of acute and persistent diarrhea of worldwide importance. J Infect Dis 202:503–505.
Bowen A, Eikmeier D, Talley P, Siston A, Smith S, Hurd J, Smith K, Leano F, Bicknese A, Norton JC, Campbell D, Centers for Disease Control and Prevention (CDC). 2015. Notes from the field: outbreaks of Shigella sonnei infection with decreased susceptibility to azithromycin among men who have sex with men—Chicago and Metropolitan Minneapolis-St. Paul, 2014. MMWR Morb Mortal Wkly Rep 64:597–598.
Gould LH, Bopp C, Strockbine N, Atkinson R, Baselski V, Body B, Carey R, Crandall C, Hurd S, Kaplan R, Neill M, Shea S, Somsel P, Tobin-D’Angelo M, Griffin PM, Gerner-Smidt P, Centers for Disease Control and Prevention. 2009. Recommendations for diagnosis of shiga toxin-producing Escherichia coli infections by clinical laboratories. MMWR Recomm Rep 58(RR-12):1–14.
Humphries RM, Linscott AJ. 2015. Practical guidance for clinical microbiology laboratories: diagnosis of bacterial gastroenteritis. Clin Microbiol Rev 28:3–31.
Stigi KA, Macdonald JK, Tellez-Marfin AA, Lofy KH.2012. Laboratory practices and incidence of non-O157 shigatoxin-producing Escherichia coli infections. Emerg Infect Dis 18:477–479.
Yam WC, Lung ML, Ng MH. 1992. Evaluation and optimization of a latex agglutination assay for detection of cholera toxin and Escherichia coli heat-labile toxin. J Clin Microbiol 30:2518–2520.
O’Hara CM. 2006. Evaluation of the Phoenix 100 ID/AST system and NID panel for identification of Enterobacteriaceae, Vibrionaceae, and commonly isolated nonenteric gram-negative bacilli. J Clin Microbiol 44:928–933.
O’Hara CM, Miller JM. 2003. Evaluation of the Vitek 2 ID-GNB assay for identification of members of the family Enterobacteriaceae and other nonenteric gram-negative bacilli and comparison with the Vitek GNI+ card. J Clin Microbiol 41:2096–2101.
Richter SS, Sercia L, Branda JA, Burnham CA, Bythrow M, Ferraro MJ, Garner OB, Ginocchio CC, Jennemann R, Lewinski MA, Manji R, Mochon AB, Rychert JA, Westblade LF, Procop GW. 2013. Identification of Enterobacteriaceae by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry using the VITEK MS system. Eur J Clin Microbiol Infect Dis 32:1571–1578.
Maiden MC, Jansen van Rensburg MJ, Bray JE, Earle SG, Ford SA, Jolley KA, McCarthy ND. 2013. MLST revisited:the gene-by-gene approach to bacterial genomics. Nat Rev Microbiol 11:728–736.
Tadesse DA, Zhao S, Tong E, Ayers S, Singh A, Bartholomew MJ, McDermott PF. 2012. Antimicrobial drug resistance in Escherichia coli from humans and food animals,United States, 1950–2002. Emerg Infect Dis 18:741–749.
Bevan ER, Jones AM, Hawkey PM. 2017. Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype. J Antimicrob Chemother 72:2145–2155.
Humphries RM, Abbott AN, Hindler JA. 2019. Understanding and addressing CLSI breakpoint revisions: a primer for clinical laboratories. J Clin Microbiol 57:e00203–19.
Van TT, Minejima E, Chiu CA, Butler-Wu SM. 2019.Don’t get wound up: revised fluoroquinolone breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol 57:e02072–18.
Bou-Antoun S, Davies J, Guy R, Johnson AP, Sheridan EA, Hope RJ. 2016. Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014. Euro Surveill 21:30329.
EUCAST. 2021. European Commitee on Antimicrobial Susceptibility Testing: Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint _tables/v_12.0_Breakpoint_Tables.pdf 221. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA,Ferraro MJ, Jones RN, Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute. 2013. Background and rationale for revised Clinical and Laboratory Standards Institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa. I. Cephalosporins and aztreonam. Clin Infect Dis 56:1301–1309.
Schuetz AN, Reyes S, Tamma PD. 2018. Point Counterpoint: Piperacillin-tazobactam should be used to treat infections with extended-spectrum-beta-lactamase positive organisms. J Clin Microbiol 56:e01917–17.
Thomson GK, Ayaz M, Lutes K, Thomson KS. 2018. An improved extended-spectrum-β-lactamase detection test utilizing aztreonam plus clavulanate. J Clin Microbiol 56:e1309–17.
CLSI. 2021. Performance standards for antimicrobial susceptibility testing. 31st informational supplement. M100. CLSI, Wayne, PA.
Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. 2000. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342:1930–1936.
Safdar N, Said A, Gangnon RE, Maki DG. 2002. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 288:996–1001.
